147 related articles for article (PubMed ID: 3034311)
21. Blood group substance, CEA, and lectins in ovarian tumors.
Dietel M; Arps H; Hölzel F; Viale G; Dell'Orto P; Kröger A; Niendorf A
Cancer Detect Prev; 1986; 9(5-6):511-20. PubMed ID: 3465441
[TBL] [Abstract][Full Text] [Related]
22. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
23. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
24. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
[TBL] [Abstract][Full Text] [Related]
25. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
26. [Differential diagnosis of borderline serous and mucinous ovarian tumors].
Bolkvadze MP; Gabuniia UA; Sheĭnina LI
Arkh Patol; 1981; 43(2):21-6. PubMed ID: 6261721
[TBL] [Abstract][Full Text] [Related]
27. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
[TBL] [Abstract][Full Text] [Related]
28. Biochemical and immunohistochemical studies on carcinoembryonic antigen of ovarian mucinous and serous tumors.
Tohya T; Iwamasa T; Maeyama M
Gynecol Oncol; 1986 Mar; 23(3):291-303. PubMed ID: 3514390
[TBL] [Abstract][Full Text] [Related]
29. [Mucinous tumors of the ovary. Anatomo-clinical aspects, histological classification, prognostic factors and histogenesis].
Bouzourene H; Genton CY
Arch Anat Cytol Pathol; 1997; 45(4):192-8. PubMed ID: 9406476
[TBL] [Abstract][Full Text] [Related]
30. Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis.
Shiohara S; Shiozawa T; Shimizu M; Toki T; Ishii K; Nikaido T; Fujii S
Cancer; 1997 Sep; 80(5):908-16. PubMed ID: 9307191
[TBL] [Abstract][Full Text] [Related]
31. [An immunohistochemical study of intestinal mucinous antigens and CEA in ovarian epithelial tumors].
Liu A; Wang M; Li H
Zhonghua Bing Li Xue Za Zhi; 1995 Dec; 24(6):366-8. PubMed ID: 8732094
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
34. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
35. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
Shi ZL
Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
[TBL] [Abstract][Full Text] [Related]
36. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study.
Huusom LD; Frederiksen K; Høgdall EV; Glud E; Christensen L; Høgdall CK; Blaakaer J; Kjaer SK
Cancer Causes Control; 2006 Aug; 17(6):821-9. PubMed ID: 16783610
[TBL] [Abstract][Full Text] [Related]
37. [Comprehensive analysis of histological types in 14006 cases of ovarian tumors].
Shi YF
Zhonghua Fu Chan Ke Za Zhi; 1992 Nov; 27(6):335-7, 379. PubMed ID: 1300276
[TBL] [Abstract][Full Text] [Related]
38. Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Yao CW; Loh SH; Cheng MF; Hsieh DS; Bai CY
Int J Gynecol Pathol; 2006 Apr; 25(2):140-6. PubMed ID: 16633062
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and prognosis of mucinous tumors of the ovary.
Kikkawa F; Nawa A; Kajiyama H; Shibata K; Ino K; Nomura S
Gynecol Oncol; 2006 Oct; 103(1):171-5. PubMed ID: 16546243
[TBL] [Abstract][Full Text] [Related]
40. [Sharing antigenic determinant of colon carcinoma between serous and mucinous tumors of the ovary].
Liu MP; Lu ZT; Chen W
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):398-400, 444. PubMed ID: 7528120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
